# reload+after+2024-01-21 00:45:32.309679
address1§321 Arsenal Street
address2§Suite 301 Building 312
city§Watertown
state§MA
zip§02472
country§United States
phone§339 217 0161
website§https://www.iteostherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
fullTimeEmployees§125
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Michel  Detheux Ph.D.', 'age': 57, 'title': 'President, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 922383, 'exercisedValue': 0, 'unexercisedValue': 9797156}, {'maxAge': 1, 'name': 'Mr. Matthew A. Call M.B.A.', 'age': 50, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 638548, 'exercisedValue': 0, 'unexercisedValue': 3446648}, {'maxAge': 1, 'name': 'Mr. Matthew  Gall', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 628451, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Yvonne  McGrath Ph.D.', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Baker', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Adi  Osovsky', 'title': 'VP & Head of Legal', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Phillipe  Brantegem', 'title': 'Vice-President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.145
priceToSalesTrailing12Months§5.757887
currency§USD
dateShortInterest§1702598400
forwardEps§-5.43
exchange§NGM
quoteType§EQUITY
shortName§iTeos Therapeutics, Inc.
longName§iTeos Therapeutics, Inc.
firstTradeDateEpochUtc§1595597400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fc26d83f-6905-3b2f-9b33-72f7f481fa2a
gmtOffSetMilliseconds§-18000000
targetHighPrice§47.0
targetLowPrice§29.0
targetMeanPrice§37.4
targetMedianPrice§34.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§21.448
grossMargins§1.0
ebitdaMargins§-1.3712801
trailingPegRatio§None
